Refine Search
(0)
(3)
(9)
(10)

Gastrointestinal Diseases

For the past few years, the market for drugs that treat gastrointestinal diseases has been highly genericized. However, the effort to develop novel drugs gained momentum in the recent past, with particular attention to biologics, especially the monoclonal antibodies. The gastrointestinal therapy area has the seventh-largest pipeline among entire disease categories, having more active pipeline drugs than therapy areas such as respiratory and ophthalmology.

Short Bowel Syndrome - Pipeline Review, H1 2018

  • $2,000
  • June 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Short Bowel Syndrome - Pipeline Review, H1 2018’, provides an overview of the Short Bowel Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Shor...

Alcoholic Hepatitis - Pipeline Review, H2 2018

  • $2,000
  • September 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Alcoholic Hepatitis - Pipeline Review, H2 2018’, provides an overview of the Alcoholic Hepatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alcoho...

Celiac Disease - Pipeline Review, H2 2018

  • $2,000
  • September 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Celiac Disease - Pipeline Review, H2 2018’, provides an overview of the Celiac Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Celiac Disease, ...

Pancreatitis - Pipeline Review, H2 2018

  • $2,000
  • September 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Pancreatitis - Pipeline Review, H2 2018’, provides an overview of the Pancreatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pancreatitis, comple...

Irritable Bowel Syndrome - Pipeline Review, H2 2018

  • $2,000
  • November 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Irritable Bowel Syndrome - Pipeline Review, H2 2018’, provides an overview of the Irritable Bowel Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development ...

Gastritis - Pipeline Review, H2 2018

  • $2,000
  • November 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Gastritis - Pipeline Review, H2 2018’, provides an overview of the Gastritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastritis, complete with a...

Peritonitis - Pipeline Review, H2 2018

  • $2,000
  • November 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Peritonitis - Pipeline Review, H2 2018’, provides an overview of the Peritonitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peritonitis, complete ...

Constipation - Pipeline Review, H1 2019

  • $2,000
  • February 2019
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Constipation - Pipeline Review, H1 2019’, provides an overview of the Constipation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Constipation, comple...

Primary Sclerosing Cholangitis - Pipeline Review, H1 2019

  • $2,000
  • February 2019
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Primary Sclerosing Cholangitis - Pipeline Review, H1 2019’, provides an overview of the Primary Sclerosing Cholangitis pipeline landscape.

The report provides comprehensive information on the therapeutics under ...

Colitis - Pipeline Review, H1 2019

  • $2,000
  • February 2019
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Colitis - Pipeline Review, H1 2019’, provides an overview of the Colitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Colitis, complete with analysi...